Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Majewski

Showing results (101-110 of 128) with videos related to

Pageof 13
Sort By:
Plos Biology|April 18, 2008
Polycomb repressive complex 2 (PRC2) restricts hematopoietic stem cell activityIan J Majewski, Marnie E Blewitt, Carolyn A de Graaf, et al.
Blood|August 29, 2013
Polycomb repressive complex 2 (PRC2) suppresses Eμ-myc lymphomaStanley C W Lee, Belinda Phipson, Craig D Hyland, et al.
The Journal of Pathology|December 5, 2012
An α-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancerIan J Majewski, Irma Kluijt, Annemieke Cats, et al.
Nature Communications|June 5, 2019
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutationsRichard W Birkinshaw, Jia-Nan Gong, Cindy S Luo, et al.
Clinical Genetics|January 16, 2015
LIMS2 mutations are associated with a novel muscular dystrophy, severe cardiomyopathy and triangular tonguesJodi Warman Chardon, A C Smith, J Woulfe, et al.
Clinical Genetics|October 30, 2013
Evidence for clinical, genetic and biochemical variability in spinal muscular atrophy with progressive myoclonic epilepsyD A Dyment, E Sell, M R Vanstone, et al.
Blood|February 4, 2015
Jarid2 regulates hematopoietic stem cell function by acting with polycomb repressive complex 2Sarah A Kinkel, Roman Galeev, Christoffer Flensburg, et al.
Clinical Genetics|July 22, 2014
Whole-exome sequencing broadens the phenotypic spectrum of rare pediatric epilepsy: a retrospective studyD A Dyment, M Tétreault, C L Beaulieu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2020
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive ChemotherapyChong Chyn Chua, Andrew W Roberts, John Reynolds, et al.
Breast Cancer Research : BCR|August 31, 2017
The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant settingTesa M Severson, Denise M Wolf, Christina Yau, et al.
Pageof 13

Showing results (101-110 of 128) with videos related to

Sort By:
Pageof 13
Plos Biology|April 18, 2008
Polycomb repressive complex 2 (PRC2) restricts hematopoietic stem cell activityIan J Majewski, Marnie E Blewitt, Carolyn A de Graaf, et al.
Blood|August 29, 2013
Polycomb repressive complex 2 (PRC2) suppresses Eμ-myc lymphomaStanley C W Lee, Belinda Phipson, Craig D Hyland, et al.
The Journal of Pathology|December 5, 2012
An α-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancerIan J Majewski, Irma Kluijt, Annemieke Cats, et al.
Nature Communications|June 5, 2019
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutationsRichard W Birkinshaw, Jia-Nan Gong, Cindy S Luo, et al.
Clinical Genetics|January 16, 2015
LIMS2 mutations are associated with a novel muscular dystrophy, severe cardiomyopathy and triangular tonguesJodi Warman Chardon, A C Smith, J Woulfe, et al.
Clinical Genetics|October 30, 2013
Evidence for clinical, genetic and biochemical variability in spinal muscular atrophy with progressive myoclonic epilepsyD A Dyment, E Sell, M R Vanstone, et al.
Blood|February 4, 2015
Jarid2 regulates hematopoietic stem cell function by acting with polycomb repressive complex 2Sarah A Kinkel, Roman Galeev, Christoffer Flensburg, et al.
Clinical Genetics|July 22, 2014
Whole-exome sequencing broadens the phenotypic spectrum of rare pediatric epilepsy: a retrospective studyD A Dyment, M Tétreault, C L Beaulieu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2020
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive ChemotherapyChong Chyn Chua, Andrew W Roberts, John Reynolds, et al.
Breast Cancer Research : BCR|August 31, 2017
The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant settingTesa M Severson, Denise M Wolf, Christina Yau, et al.
Pageof 13